Join
Live feed
·
PRReleasevia Quantisnow
Invivyd Inc. logo

Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome

ByQuantisnow·Wall Street's wire, on your screen.
IVVD· Invivyd Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IVVD (Invivyd Inc.) and more on Quantisnow.